Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone.
- G. von Philipsborn, J. Gries, H. Teschendorf
- Biology, ChemistryArzneimittel-Forschung
- 1984
The results show low CNS activity of propafenone which is even lower for the metabolite but which is distinctly higher for lidocaine and - related to the antiarrhythmic potency - for flecainide, too.
Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action.
- D. Lenke, J. Gries, R. Kretzschmar
- Biology, ChemistryArzneimittel-Forschung
- 1981
Pharmacological studies on the mechanism of action of 4-amino-6-methoxy-1-phenyl-pyridazinim methyl sulfate (ameziniummetilsulfate, LU 1631, Regulton), in the following briefly called amezinium, are…
6-Aryl-4,5-dihydro-3(2H)-pyridazinones. A new class of compounds with platelet aggregation inhibiting and hypotensive activities.
- M. Thyes, H. Lehmann, D. Lenke
- Chemistry, BiologyJournal of Medicinal Chemistry
- 1 June 1983
The antiaggregation activity of compounds of this type is in vitro up to 16000 times and ex vivo up to 370 times greater than that of acetylsalicylic acid; the hypotensive action is up to 40 times as great as that of the comparative substance dihydralazine.
Development of Hypertension and Life Span in Stroke‐Prone Spontaneously Hypertensive Rats During Oral Long‐Term Treatment with Various Antihypertensive Drugs
- J. Gries, R. Kretzschmar, B. Neumann
- Medicine, ChemistryJournal of Cardiovascular Pharmacology
- 1989
In stroke-prone spontaneously hypertensive rats, oral long-term treatment with verapamil, propranolol, hydrochlorothiazide, and dihydralazine attenuated the development of hypertension and it is assumed that calcium antagonism and β-receptor blockade prolong the life span, not only due to their blood-pressure-lowering mechanism, but also to the additional protective effects.
Pharmacology of amezinium, a novel antihypotensive drug. I. Comparative studies of the effect on blood pressure and heart rate.
- J. Gries, J. Schuster, H. Giertz, H. Lehmann, D. Lenke, W. Worstmann
- MedicineArzneimittel-Forschung
- 1981
Synthesis and antihypertensive activity of new 6-heteroaryl-3-hydrazinopyridazine derivatives.
- G. Steiner, J. Gries, D. Lenke
- ChemistryJournal of Medicinal Chemistry
- 1981
The synthesis and pharmacological activity of new 6-heteroaryl-3-hydrazinopyridazines with antihypertensive action and 6-Imidazol-1-yl derivatives have proved particularly active and achieves 4.9 times the activity of dihydralazine when administered orally to spontaneously hypertensive rats.
2-(Isoxazolylethenyl)phenoxypropanolamines: a new class of beta-receptor antagonists with antihypertensive activity.
- A. Franke, F. Frickel, J. Gries, D. Lenke, R. Schlecker, P. D. Thieme
- Chemistry, BiologyJournal of Medicinal Chemistry
- 1 December 1981
Synthesis of a series of (E)-1-amino-3-[2-(2-isoxazolylethenyl)phenoxyl-2-propanols] was found to have beta- and alpha-adrenergic blocking properties, as well as hypotensive and antihypertensive properties, and structure-activity considerations showed that anti Hypertensive potency was more sensitive to structural variations than beta- adrenoceptor antagonistic activity.
NEW β-SYMPATHOLYTIC AGENTS: SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF ISOMERIC BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES
- A. Franke, F. Frickel, J. Gries, H. Lehmann, D. Lenke, U. Ohnsorge
- Chemistry
- 10 March 1981
[Pharmacological characterization of the new highly potent beta-adrenergic receptor blocker soquinolol].
- J. Gries, L. Unger, F. Zimmermann
- Biology, ChemistryArzneimittel-Forschung
- 1 September 1988
Soquinolol is characterized as a highly potent non-subtype-selective beta-adrenergic receptor blocker, which is devoid of any intrinsic sympathomimetic activity and shows good enteral efficacy and long duration of action.
The protective mechanism of estrogen on high blood pressure
- A. Eiff, H. Lutz, J. Gries, R. Kretzschmar
- Medicine, BiologyBasic Research in Cardiology
- 1 March 1985
Treatment with 17-betaestradiolbenzoate had an antihypertensive effect in male rats, but no prolongation of the life-span was obtained, and in male Rats treated at an earlier stage, the development of hypertension was inhibited by EB.
...
...